Drugs / anti-PSMA CAR-NK
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07298239 | Dec 2025 → Apr 2028 expected | castration-resistant prostate carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 0 | NCT07156045 | Sep 2025 → Dec 2026 expected | castration-resistant prostate carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-PSMA CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07156045 ↗ |
| Action | Deplete | “engineered natural killer cells designed to precisely recognize and kill prostate cancer cells expressing the prostate-specific membrane antigen” NCT07298239 ↗ |
| Modality | Cell therapy | “Targeting PSMA CAR-NK cells” NCT07156045 ↗ |